Kevin Gao (@XGaoKevin) profile picture

Ph.D candidate in Molecular Pharmacology and Experimental Therapeutics at #MayoClinic. Sudden death genomics I Cardiac channelopathies

Joined May 2021
Photo by Kevin Gao (@XGaoKevin)
In the life of a mentor, this past wk was unforgettable. 3 of my PhD students: ⁦@XGaoKevin⁩ ⁦@GarmanyRamin⁩ & ⁦@sahejbains⁩ successfully defended their PhD thesis. I started as their adviser, grew into their mentor, and became their “father”. So PROUD of them!
2
5
1
41
4,850
I got to start my week ⁦@MayoClinic⁩ ⁦@MayoGradSchool⁩ w/ a truly special “Team Ackerman” event. ⁦@XGaoKevin⁩ successfully defended his PhD today & soon will be recognized as Dr. Gao. So excited for & proud of Kevin! 🤗 Next step - postdoc ⁦@StanfordCVI⁩
4
38
2,762
Strong work by @XGaoKevin presenting on how BrS, LQT3 and MEPPC-causative variants have distinct 3D clustering patterns @ #HRS2023! Potential new tool in the battle to interpret SCN5A VUS?
1
2
11
848
⁦@XGaoKevin⁩ made ⁦@MayoClinic⁩ ⁦@MayoGradSchool⁩ & my team look very good here ⁦@HRSonline⁩ #HRS2023 w/ his talk on the 3-D structural analysis of the sodium channel & its ability to help distinguish “noise” from true #disease causing #genetic variants.
4
24
3,312
Thanks @hrs_journal & congrats to my @MayoGradSchool PhD student @XGaoKevin on his characterization of a lidocaine/mexiletine-insensitive LQT3-causative mutation. Unfortunately, we were unable to become smart enough soon enough for the beautiful girl who owned this variant.
Functional Characterization and Identification of a Therapeutic for a Novel SCN5A-F1760C Variant Causing Type 3 Long QT Syndrome Refractory to All Guideline-Directed Therapies, by @MJAckermanMDPhD and colleagues heartrhythmjournal.com/artic…
1
5
12
2,078
Excited to share our latest work in @hrs_journal on characterization of a novel SCN5A variant causing LQT3. Phenytoin could be effective as a variant specific therapy. Thanks @MJAckermanMDPhD for the mentorship!
Functional Characterization and Identification of a Therapeutic for a Novel SCN5A-F1760C Variant Causing Type 3 Long QT Syndrome Refractory to All Guideline-Directed Therapies, by @MJAckermanMDPhD and colleagues heartrhythmjournal.com/artic…
2
1
5
863
Also big shout out to @marissastutzman @DaveTester77 @JohnGiudicessi and others not on twitter. This is truly a team effort!
1
119
Very excited to share my work on iPSC-CM modeling for MEPPC at #AHA22 Grateful to have the opportunity to work under the mentorship of @MJAckermanMDPhD @JohnGiudicessi and the amazing team at @MayoClinicWSRGH
Very fortunate to have @XGaoKevin on my team. Kevin is a PhD student @MayoGradSchool and just finished is first ever presentation @AHAMeetings. The model system that he has developed for Multifocal Ectopic Purkinje-Related PVCs is really cool. Great work Kevin.
4
Very fortunate to have @XGaoKevin on my team. Kevin is a PhD student @MayoGradSchool and just finished is first ever presentation @AHAMeetings. The model system that he has developed for Multifocal Ectopic Purkinje-Related PVCs is really cool. Great work Kevin. – at Chicago, IL
4
1
13
Our latest study on a novel functional variant outside SCN5A encoded Nav1.5 voltage-sensing domain causing multifocal ectopic Purkinje-related premature contractions (MEPPC) is now available on @HRS_CaseReports. @JohnGiudicessi @MJAckermanMDPhD doi.org/10.1016/j.hrcr.2021.…
2
1
15
My first @AHAMeetings poster presentation on SCN5A-associated Multifocal Ectopic Purkinje-Related Premature Contractions (MEPPC) goes live! Thanks to the mentorship from @MJAckermanMDPhD @JohnGiudicessi
1
1
19
My PhD student ⁦@XGaoKevin⁩ from ⁦@MayoClinic ⁦@MayoGradSchool⁩ presenting his poster now ⁦@AHAScience⁩ #AHA2021 virtual meeting. Cool work & neat thesis on a relatively new SCN5A-opathy. Way to go Kevin.
2
9
44
Passed my oral qualifying exam and finally a Ph.D candidate at @MayoGradSchool. Thank you @MJAckermanMDPhD for you mentorship!
2
1
1
21
CONGRATS ⁦@XGaoKevin⁩ on his first poster presentation at #HRS2021 detailing effect of #mexiletine on 3 different #LQTS re-engineered #heart cell models from pts w/ LQT1, LQT2, & LQT3. This Rx is not for just LQT3 anymore. At bench & at bedside, remember it for tough LQT2.
1
1
15